4-羟基-3-甲基-5-硝基苯甲醛 | 54674-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-羟基-3-甲基-5-硝基苯甲醛
• 英文名称: 4-hydroxy-3-methyl-5-nitrobenzaldehyde
• CAS: 54674-91-8
• 化学式: C₈H₇NO₄
• 分子量: 181.148
• InChiKey: OYMIIKBORUBGQN-UHFFFAOYSA-N

物化性质

• 熔点：
  152 °C
• 沸点：
  290.3±40.0 °C(Predicted)
• 密度：
  1.419±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-羟基-3-甲基-5-硝基苯甲醛 在 sodium dithionite 、 氨 、 双氧水 、 sodium hydride 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 45.75h， 生成 替米沙坦甲酯
  参考文献：
  名称：

  Highly practical and cost-efficient synthesis of telmisartan: an antihypertensive drug

  摘要：

  A novel and cost-efficient strategy for synthesis of an antihypertensive drug telmisartan, a substituted bis-benzimidazole derivative, is described. The key strategy is the construction of bis-benzimidazole 4 by reductive cyclization of o-nitroanilines 11 with butyl aldehyde and cyclocondensation of aromatic aldehydes 9 with o-phenylenediamine, then N-alkylation is allowed to give the target compound telmisartan after hydrolysis. The simple operation and workup procedure, along with the low production costs, make it suitable for industrial production and will benefits those with cardiovascular disease. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.01.056
• 作为产物：
  描述：

  3-甲基-4-羟基苯甲醛 在 硫酸 、 硝酸 作用下， 生成 4-羟基-3-甲基-5-硝基苯甲醛
  参考文献：
  名称：

  Structure–activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents

  摘要：

  The structure-activity relationship of phenylpyrazole derivative 1 was investigated for the development of novel anti-HIV agents. Initial efforts revealed that the diazenyl group can be replaced by an aminomethylene group. In addition, we synthesized various derivatives by the reductive amination of benzaldehydes with 5-aminopyrazoles and carried out parallel structural optimization on the benzyl group and the pyrazole ring. This optimization led to a six-fold more potent derivative 32j than the lead compound 1, and this derivative has a 3',4'-dichloro-(1,1'-biphenyl)-3-yl group. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.026

文献信息

• ENTACAPONE-DERIVATIVES
  申请人：Hansen Klaus

  公开号：US20080103191A1

  公开（公告）日：2008-05-01

  Pharmaceutical composition comprising one or more entacapone derivatives and one or more pharmaceutically acceptable carriers, a process for producing the pharmaceutical composition, specific entacapone derivatives, a process for the preparation of entacapone derivatives, and the use of the entacapone derivatives for the preparation of a medicament.

  包括一种或多种恩他卡朋衍生物和一种或多种药用可接受载体的药物组合物，生产该药物组合物的方法，特定的恩他卡朋衍生物，制备恩他卡朋衍生物的方法，以及利用恩他卡朋衍生物制备药物的用途。
• [EN] HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY<br/>[FR] DÉRIVÉS D'HÉMIASTERLINE POUR CONJUGAISON ET THÉRAPIE
  申请人：SUTRO BIOPHARMA INC

  公开号：WO2016123582A1

  公开（公告）日：2016-08-04

  Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W1, W4, W5, SG, and R are as described herein.

  本文提供了半星菱素衍生物，以及与之结合的共轭物，包含这些衍生物或共轭物的组合物，生产这些衍生物和共轭物的方法，以及利用这些衍生物、共轭物和组合物治疗细胞增殖的方法。这些衍生物、共轭物和组合物在治疗和预防细胞增殖和癌症的方法中很有用，也可用于检测细胞增殖和癌症的方法，以及诊断细胞增殖和癌症的方法。在一个实施例中，半星菱素衍生物符合公式1000：或其药用可接受的盐、溶剂化合物或互变异构体，其中Ar、L、W1、W4、W5、SG和R如本文所述。
• Small Molecule Xanthine Oxidase Inhibitors and Methods of Use
  申请人：BAYLOR COLLEGE OF MEDICINE

  公开号：US20140163045A1

  公开（公告）日：2014-06-12

  Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

  提供了小分子黄嘌呤氧化酶抑制剂，以及它们在治疗痛风或高尿酸血症中的使用方法。
• Benzoxazin-3-ones and derivatives thereof as therapeutic agents
  申请人：——

  公开号：US20040121996A1

  公开（公告）日：2004-06-24

  The present invention provides compounds of Formula I 1 wherein W, Q, E, D, R 6 , R 7 , R 8 , Y, K, R 9 , R 10 , R 12 , G, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了I式化合物，其中W，Q，E，D，R6，R7，R8，Y，K，R9，R10，R12，G和表示为“*”的双键具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病，心血管疾病和癌症。还提供了包含一种或多种I式化合物的制药组合物。
• Methods for the preparation of Entacapone
  申请人：Venkateswarlu Jasti

  公开号：US20070060767A1

  公开（公告）日：2007-03-15

  The invention disclosed in this application relates to an improved process for the preparation of Entacapone. In one embodiment the process involves: (i) reacting a 3-alkoxy-4-hydroxy-5-nitrobenzadehyde with N,N-diethylaminocyanoacetamide in the presence of a mild acid catalyst and a solvent, to provide a 3-O-alkylated Entacapone, and treating the 3-O-alkylated Entacapone with an acid catalyst in the presence of an organic base to provide Entacapone.

  这个申请中披露的发明涉及一种改进的恩他卡韦制备工艺。在一个实施例中，该工艺包括：(i) 在温和酸催化剂和溶剂的存在下，将3-烷氧基-4-羟基-5-硝基苯甲醛与N,N-二乙基氨基丙腈反应，得到3-O-烷基化的恩他卡韦，并在有机碱的存在下，用酸催化剂处理3-O-烷基化的恩他卡韦，得到恩他卡韦。